北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 妇科  > 期刊论文
学科主题: 临床医学
题名:
Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center
作者: Zhang Guo; Li Xiao-ping; Liu Bing-jie; Wang Jian-liu; Wang Shi-jun; Cui Heng; Wei Li-hui
关键词: ovarian cancer ; oxaliplatin ; drug-resistance ; recurrent
刊名: CHINESE MEDICAL JOURNAL
发表日期: 2013-12-05
DOI: 10.3760/cma.j.issn.0366-6999.20130799
卷: 126, 期:23, 页:4477-4482
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal
研究领域[WOS]: General & Internal Medicine
关键词[WOS]: PEGYLATED LIPOSOMAL DOXORUBICIN ; PHASE-II ; CARCINOMA ; TRIAL
英文摘要:

Background Combination paclitaxel and carboplatin is currently a first-line regimen for ovarian cancer. However, many patients develop tumor recurrence or drug resistance to this regimen. The study aims to investigate the effectiveness and safety of an oxaliplatin + epirubicin + ifosfamide regimen for the treatment of recurrent and drug-resistant epithelial ovarian cancer.

Methods A retrospective analysis of 73 patients with recurrent and drug-resistant ovarian cancer was performed; 38 cases of them received oxaliplatin + epirubicin + ifosfamide regimens (IAP group), 35 patients received non-oxaliplatin-based chemotherapy regimens (control group). The therapeutic effects and side effects of the oxaliplatin + epirubicin + ifosfamide regimen were analyzed and summarized. Kaplan-Meier survival curves and Cox proportional hazards regression were used to compare progression-free and overall survival between the two groups.

Results Of the 38 patients in the IAP group, 14 patients (36.84%) achieved complete remission, 12 (31.58%) achieved partial remission, 2 (5.26%) achieved stable disease and 10 (26.32%) developed progressive disease. The overall effective rate (complete or partial remission) of the IAP regime was 68.42%. While, of the 35 patients in the control group, 12 patients (34.29%) achieved complete remission, 3 (8.57%) achieved partial remission, 5 (14.29%) achieved stable disease and 15 (42.86%) developed progressive disease. The overall effective rate was 42.86%, which was lower than that in the IAP group (P=0.035, chi(2)=4.836). Progression-free survival was 9.5 months (0-64 months) in the IAP group vs. 3 months (0-74 months) in the non-oxaliplatin group (P=0.014 by Kaplan-Meier survival curves; HR=2.260; 95%CI 1.117-4.573; P=0.023 by Cox proportional hazards regression). Median overall survival was 46 months (9-124 months) in the IAP group vs. 35 months (9-108 months) in non-oxaliplatin group (P=0.018 by Kaplan-Meier survival curves; HR=2.272; 95%CI 1.123-4.598; P=0.022 by Cox proportional hazards regression). In IAP group, 15.79% (6/38) of the patients suffered grade III-IV bone marrow arrest. The main non-hematological side effects of the IAP regimen included nausea and vomiting (21.05%, 8/38), peripheral neurotoxicity (15.79%, 6/38) and hepatic or renal lesions (2.63%, 1/38). The main side effects of the two chemotherapy regimens showed no statistical difference.

Conclusion The oxaliplatin-based IAP regimen is potentially effective for salvage chemotherapy in patients with recurrent and drug-resistant ovarian cancer, with a better therapeutic effect and tolerable side effects.

语种: 英语
WOS记录号: WOS:000329084100014
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/54356
Appears in Collections:北京大学第二临床医学院_妇科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ Peoples Hosp, Dept Gynecol, Beijing 100044, Peoples R China

Recommended Citation:
Zhang Guo,Li Xiao-ping,Liu Bing-jie,et al. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center[J]. CHINESE MEDICAL JOURNAL,2013,126(23):4477-4482.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhang Guo]'s Articles
[Li Xiao-ping]'s Articles
[Liu Bing-jie]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhang Guo]‘s Articles
[Li Xiao-ping]‘s Articles
[Liu Bing-jie]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace